GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » Piotroski F-Score

BMY (Bristol-Myers Squibb Co) Piotroski F-Score : 6 (As of Jul. 25, 2025)


View and export this data going back to 1952. Start your Free Trial

What is Bristol-Myers Squibb Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Bristol-Myers Squibb Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Bristol-Myers Squibb Co's Piotroski F-Score or its related term are showing as below:

BMY' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 9
Current: 6

During the past 13 years, the highest Piotroski F-Score of Bristol-Myers Squibb Co was 9. The lowest was 3. And the median was 6.


Bristol-Myers Squibb Co Piotroski F-Score Historical Data

The historical data trend for Bristol-Myers Squibb Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Piotroski F-Score Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 8.00 6.00 7.00 4.00

Bristol-Myers Squibb Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 5.00 4.00 6.00

Competitive Comparison of Bristol-Myers Squibb Co's Piotroski F-Score

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Net Income was 1680 + 1211 + 72 + 2456 = $5,419 Mil.
Cash Flow from Operations was 2326 + 5591 + 4439 + 1954 = $14,310 Mil.
Revenue was 12201 + 11892 + 12342 + 11201 = $47,636 Mil.
Gross Profit was 8934 + 8935 + 7530 + 8168 = $33,567 Mil.
Average Total Assets from the begining of this year (Mar24)
to the end of this year (Mar25) was
(99031 + 94646 + 93670 + 92603 + 92427) / 5 = $94475.4 Mil.
Total Assets at the begining of this year (Mar24) was $99,031 Mil.
Long-Term Debt & Capital Lease Obligation was $47,513 Mil.
Total Current Assets was $30,783 Mil.
Total Current Liabilities was $24,070 Mil.
Net Income was 2073 + 1928 + 1762 + -11911 = $-6,148 Mil.

Revenue was 11226 + 10966 + 11477 + 11865 = $45,534 Mil.
Gross Profit was 8350 + 8460 + 8732 + 8933 = $34,475 Mil.
Average Total Assets from the begining of last year (Mar23)
to the end of last year (Mar24) was
(94281 + 93489 + 91263 + 95159 + 99031) / 5 = $94644.6 Mil.
Total Assets at the begining of last year (Mar23) was $94,281 Mil.
Long-Term Debt & Capital Lease Obligation was $51,050 Mil.
Total Current Assets was $28,669 Mil.
Total Current Liabilities was $25,822 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Bristol-Myers Squibb Co's current Net Income (TTM) was 5,419. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Bristol-Myers Squibb Co's current Cash Flow from Operations (TTM) was 14,310. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar24)
=5419/99031
=0.05472024

ROA (Last Year)=Net Income/Total Assets (Mar23)
=-6148/94281
=-0.06520932

Bristol-Myers Squibb Co's return on assets of this year was 0.05472024. Bristol-Myers Squibb Co's return on assets of last year was -0.06520932. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Bristol-Myers Squibb Co's current Net Income (TTM) was 5,419. Bristol-Myers Squibb Co's current Cash Flow from Operations (TTM) was 14,310. ==> 14,310 > 5,419 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=47513/94475.4
=0.50291399

Gearing (Last Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=51050/94644.6
=0.53938629

Bristol-Myers Squibb Co's gearing of this year was 0.50291399. Bristol-Myers Squibb Co's gearing of last year was 0.53938629. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar25)=Total Current Assets/Total Current Liabilities
=30783/24070
=1.27889489

Current Ratio (Last Year: Mar24)=Total Current Assets/Total Current Liabilities
=28669/25822
=1.11025482

Bristol-Myers Squibb Co's current ratio of this year was 1.27889489. Bristol-Myers Squibb Co's current ratio of last year was 1.11025482. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Bristol-Myers Squibb Co's number of shares in issue this year was 2040. Bristol-Myers Squibb Co's number of shares in issue last year was 2023. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=33567/47636
=0.70465614

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=34475/45534
=0.75712654

Bristol-Myers Squibb Co's gross margin of this year was 0.70465614. Bristol-Myers Squibb Co's gross margin of last year was 0.75712654. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar24)
=47636/99031
=0.48102109

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar23)
=45534/94281
=0.48296051

Bristol-Myers Squibb Co's asset turnover of this year was 0.48102109. Bristol-Myers Squibb Co's asset turnover of last year was 0.48296051. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+0+0+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Bristol-Myers Squibb Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Bristol-Myers Squibb Co  (NYSE:BMY) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Bristol-Myers Squibb Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co Business Description

Address
Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Executives
Samit Hirawat officer: Chief Medical Offr., Drug Dev. BRISTOL-MYERS SQIUBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Christopher S. Boerner officer: EVP, Chief Commercial Officer 21823 30TH DRIVE S, BOTHELL WA 98021
Samuels Theodore R. Ii director 1990 E. GRAND AVE., EL SEGUNDO CA 90245
Cari Gallman officer: EVP, Corporate Affairs BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Ann Powell Judge officer: SVP, Human Resources BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Robert M Plenge officer: EVP, Chief Research Officer C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Rupert Vessey officer: Pres., Research & Early Dev. C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Adam Lenkowsky officer: EVP, Chief Commercial Officer BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Giovanni Caforio officer: EVP & Chief Commercial Officer BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
David V Elkins officer: EVP, Chief Financial Officer C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Deepak Bhatt director BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Sandra Leung officer: Vice President and Secretary C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Sharon Greenlees officer: SVP & Controller BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Karin Shanahan officer: EVP, Glob. Prod. Dev. & Supply BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Gregory Scott Meyers officer: EVP, Chief Digital & Tech Off. BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543